Cargando…
IL-6/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 induction
BACKGROUND: The quality and quantity of tumor neoantigens derived from tumor mutations determines the fate of the immune response in cancer. Frameshift mutations elicit better tumor neoantigens, especially when they are not targeted by nonsense-mediated mRNA decay (NMD). For tumor progression, malig...
Autores principales: | Meraviglia-Crivelli, Daniel, Villanueva, Helena, Zheleva, Angelina, Villalba-Esparza, María, Moreno, Beatriz, Menon, Ashwathi Puravankara, Calvo, Alfonso, Cebollero, Javier, Barainka, Martin, de los Mozos, Igor Ruiz, Huesa-Berral, Carlos, Pastor, Fernando |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703761/ https://www.ncbi.nlm.nih.gov/pubmed/36443756 http://dx.doi.org/10.1186/s12943-022-01679-6 |
Ejemplares similares
-
A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression
por: Meraviglia-Crivelli, Daniel, et al.
Publicado: (2022) -
Modulating T Cell Responses by Targeting CD3
por: Menon, Ashwathi Puravankara, et al.
Publicado: (2023) -
Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune System
por: Meraviglia-Crivelli, Daniel, et al.
Publicado: (2022) -
ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity
por: Soldevilla, Mario Martínez, et al.
Publicado: (2019) -
Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?
por: Sola, Mayte, et al.
Publicado: (2020)